Papillary Thyroid Cancer: Monitoring and Therapy

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 3, 2007, Pages 753-778

  Tuttle, R Michael ^a,b   Leboeuf, Rébecca ^c   Martorella, Andrew J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE; THYROGLOBULIN;

ASPIRATION BIOPSY; CANCER STAGING; CLINICAL FEATURE; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LYMPHADENECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBTOTAL THYROIDECTOMY; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; WHOLE BODY SCINTISCANNING;

CARCINOMA, PAPILLARY; EARLY DIAGNOSIS; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PRACTICE GUIDELINES; RECURRENCE; RISK ASSESSMENT; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 34547285013     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.04.004     Document Type: Review

References (69)

1. American Cancer Society. Cancer facts and figures 2006. 2006; Available at: www.cancer.org. Accessed November 1, 2006.
2. Ries LA, Harkins D, Krapcho M, et al. SEER cancer statistics review, 1975-2003, based on November 2005 SEER data submission. 2006; Available at: http://seer.cancer.gov/csr/1975_2003/. Accessed November 1, 2006.
3. Hundahl S.A., Cady B., Cunningham M.P., et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89 1 (2000) 202-217
4. Gilliland F.D., Hunt W.C., Morris D.M., et al. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79 3 (1997) 564-573
5. Mazzaferri E.L., and Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86 4 (2001) 1447-1463
6. Davies L., and Welch H.G. Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 135 3 (2006) 451-457
7. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 18 (2006) 2164-2167
8. Schneider A.B., and Sarne D.H. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab 1 2 (2005) 82-91
9. Nagataki S., and Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid 12 10 (2002) 889-896
10. Sherman S.I. Thyroid carcinoma. Lancet 361 9356 (2003) 501-511
11. Sherman SI. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, Thyroid Cancer V.2.2006. 2006; Available at: http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf. Accessed November 1, 2006.
12. Malchoff C.D., and Malchoff D.M. Familial nonmedullary thyroid carcinoma. Cancer Control 13 2 (2006) 106-110
13. Chow S.M., Law S.C., Chan J.K., et al. Papillary microcarcinoma of the thyroid: prognostic significance of lymph node metastasis and multifocality. Cancer 98 1 (2003) 31-40
14. Grebe S.K., and Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5 1 (1996) 43-63
15. Ito Y., Uruno T., Nakano K., et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13 4 (2003) 381-387
16. McConahey W.M., Hay I.D., Woolner L.B., et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61 12 (1986) 978-996
17. Nam-Goong I.S., Kim H.Y., Gong G., et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 60 1 (2004) 21-28
18. Scheumann G.F., Gimm O., Wegener G., et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18 4 (1994) 559-567 [discussion: 567-8]
19. Arturi F., Russo D., Giuffrida D., et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 82 5 (1997) 1638-1641
20. Qubain S.W., Nakano S., Baba M., et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 131 3 (2002) 249-256
21. Hay I.D. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19 3 (1990) 545-576
22. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97 5 (1994) 418-428
23. Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26 8 (2002) 879-885
24. BTA. British Thyroid Association and Royal College of Physicians: guidelines for the management of thyroid cancer in adults 2002. Available at: www.british-thyroid-association.org. Accessed November 1, 2006.
25. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 2 (2006) 109-142
26. Pacini F., Schlumberger M., Dralle H., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 6 (2006) 787-803
27. ThyroidCarcinomaTaskForce. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 7 3 (2001) 202-220
28. Watkinson J.C. The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl Med Commun 25 9 (2004) 897-900
29. Brierley J.D., Panzarella T., Tsang R.W., et al. A comparison of different staging systems predictability of patient outcome: thyroid carcinoma as an example. Cancer 79 12 (1997) 2414-2423
30. Dean D.S., and Hay I.D. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7 3 (2000) 229-239
31. Byar D.P., Green S.B., Dor P., et al. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15 8 (1979) 1033-1041
32. Hay I.D., Grant C.S., Taylor W.F., et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102 6 (1987) 1088-1095
33. Cady B., and Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104 6 (1988) 947-953
34. Hay I.D., Bergstralh E.J., Goellner J.R., et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114 6 (1993) 1050-1057 [discussion: 1057-8]
35. Shaha A.R., Loree T.R., and Shah J.P. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118 6 (1995) 1131-1136 [discussion: 1136-8]
36. Sherman S.I., Brierley J.D., Sperling M., et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83 5 (1998) 1012-1021
37. AJCC Cancer Staging Manual. 6th edition. New York: Springer-Verlag; 2002.
38. Shimamoto K., Satake H., Sawaki A., et al. Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol 29 1 (1998) 4-10
39. Solorzano C.C., Carneiro D.M., Ramirez M., et al. Surgeon-performed ultrasound in the management of thyroid malignancy. Am Surg 70 7 (2004) 576-580 [discussion: 580-2]
40. Hay I.D., Grant C.S., Bergstralh E.J., et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?. Surgery 124 6 (1998) 958-964 [discussion: 964-6]
41. Shaha A.R., Shah J.P., and Loree T.R. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 4 4 (1997) 328-333
42. DeGroot L.J., Kaplan E.L., McCormick M., et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71 2 (1990) 414-424
43. Mazzaferri E.L., and Jhiang S.M. Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc 106 (1994) 151-168 [discussion: 168-70]
44. Samaan N.A., Schultz P.N., Hickey R.C., et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75 3 (1992) 714-720
45. Sawka A.M., Thephamongkhol K., Brouwers M., et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89 8 (2004) 3668-3676
46. Taylor T., Specker B., Robbins J., et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129 8 (1998) 622-627
47. Sherman S.I., Tielens E.T., Sostre S., et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78 3 (1994) 629-634
48. Kim S., Wei J.P., Braveman J.M., et al. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 139 4 (2004) 390-394 [discussion: 393-4]
49. Sanders L.E., and Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133 4 (1998) 419-425
50. Sugitani I., and Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46 1 (1999) 209-216
51. Mazzaferri E.L. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 7 2 (1997) 265-271
52. Lee N., and Tuttle R.M. External beam radiation for differentiated thyroid cancer. Endocr Relat Cancer 13 4 (2006) 971-977
53. Biondi B., Filetti S., and Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1 1 (2005) 32-40
54. McGriff N.J., Csako G., Gourgiotis L., et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34 7-8 (2002) 554-564
55. Cooper D.S., Specker B., Ho M., et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8 9 (1998) 737-744
56. Pujol P., Daures J.P., Nsakala N., et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81 12 (1996) 4318-4323
57. Spencer C.A. Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. Endocr Pract 6 6 (2000) 481-484
58. Robbins R.J., Srivastava S., Shaha A., et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 89 12 (2004) 6010-6016
59. Pacini F., Molinaro E., Castagna M.G., et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88 8 (2003) 3668-3673
60. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88 4 (2003) 1433-1441
61. Spencer C.A., Bergoglio L.M., Kazarosyan M., et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 90 10 (2005) 5566-5575
62. Spencer C.A. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 89 8 (2004) 3702-3704
63. Wong K.T., and Ahuja A.T. Ultrasound of thyroid cancer. Cancer Imaging 5 (2005) 157-166
64. Larson S.M., and Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 37 2 (2002) 169-174
65. Stokkel M.P., Duchateau C.S., and Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 50 1 (2006) 78-87
66. Wang W., Larson S.M., Tuttle R.M., et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11 12 (2001) 1169-1175
67. Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91 2 (2006) 498-505
68. Pacini F., Agate L., Elisei R., et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86 9 (2001) 4092-4097
69. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 8 (2006) 2892-2899